Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Immunodiagnostics group Oncimmune said it expected to book a large rise in revenue, in line with market expectations.
Revenue for the year through March was seen increasing to £5.6 million, up from £0.7 million year-on-year.
Oncimmune said it also managed its cost base tightly during the year following the implementation of a cost reduction programme in the 2020 financial year.
Looking forward to the 2022 financial year, it said it was confident of delivering on revenue expectations, citing a high degree of revenue visibility.